ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.11), $0.11 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $19.25 million versus the consensus estimate of $18.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Wells Fargo Starts Bread Financial Holdings (BFH) at Equal Weight
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• UBS Upgrades SD Guthrie (SDG:MK) to Buy